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WW domain-containing oxidoreductase (WWOX), a putative tumour suppressor, is suggested to be involved in the
hyperphosphorylation of Alzheimer’s Tau. Tau is a microtubule-associated protein that has an important role in microtubule
assembly and stability. Glycogen synthase kinase 3b (GSK3b) has a vital role in Tau hyperphosphorylation at its microtubule-
binding domains. Hyperphosphorylated Tau has a low afﬁnity for microtubules, thus disrupting microtubule stability.
Bioinformatics analysis indicated that WWOX contains two potential GSK3b-binding FXXXLI/VXRLE motifs. Immunoﬂuores-
cence, immunoprecipitation and molecular modelling showed that WWOX interacts physically with GSK3b. We demonstrated
biochemically that WWOX can bind directly to GSK3b through its short-chain alcohol dehydrogenase/reductase domain.
Moreover, the overexpression of WWOX inhibited GSK3b-stimulated S396 and S404 phosphorylation within the microtubule
domains of Tau, indicating that WWOX is involved in regulating GSK3b activity in cells. WWOX repressed GSK3b activity,
restoredthemicrotubuleassemblyactivityofTauandpromotedneuriteoutgrowthinSH-SY5Ycells.Conversely,RNAi-mediated
knockdown of WWOX in retinoic acid (RA)-differentiated SH-SY5Y cells inhibited neurite outgrowth. These results suggest that
WWOX is likely to be involved in regulating GSK3b activity, reducing the level of phosphorylated Tau, and subsequently
promoting neurite outgrowth during neuron differentiation. In summary, our data reveal a novel mechanism by which WWOX
promotes neuronal differentiation in response to RA.
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WWdomain-containingoxidoreductase(WWOX/WOX1/FOR)
1
is a 46kDa protein that has been implicated in human
tumourigenesis, nervous system development and Alzheimer’s
disease (AD).
2–4 WWOX contains two N-terminal WW domains
(containing conserved tryptophan residues) and one COOH-
terminal short-chain alcohol dehydrogenase/reductase (ADH/
SDR) domain. Both the WW and ADH domains mediate
protein–protein interactions. The WWOX has been reported to
bind to many proteins, including p53, p73, erythroblastic
leukaemia viral oncogene homolog 4, ezrin, activator protein-2
g, small integral membrane protein of the lysosome/late
endosome, c-Jun N-terminal kinase 1 and mouse double
mutant 2.
5,6 Although some studies have suggested that
WWOX might have a critical role in regulating Tau hyper-
phosphorylation,
2 the details of this regulation remain unclear.
Glycogen synthase kinase 3b (GSK3b), a serine/threonine
kinase that was ﬁrst identiﬁed based on its ability to
phosphorylate glycogen synthase and regulate glycogen
metabolism, is now known to be a key kinase in several
important signalling pathways. The dysregulation of GSK3b is
involved in several major human diseases, including diabetes,
cancer, AD and bipolar disorder.
7 Researchers have reported a
number of proteins that associate with GSK3b and regulate its
activity. The strongest examples is Axin, which are involved in
the Wnt signalling pathway.
2,8 Chou et al.
9 used the yeast two-
hybrid method to identify a novel GSK3b interacting protein,
GSKIP, which can bind to GSK3b and inhibit its kinase activity.
The role of GSK3b in regulating neural cell differentiation is
controversial. GSK3b has been shown to facilitate neurite
outgrowth by preventing E2F1 from inhibiting the transcription
of the cell cycle inhibitors p21 and p15.
10 However, other
evidence has indicated that the inactivation of GSK3b results
in collapsin response mediator protein 2 (CRMP-2) depho-
sphorylation, which leads to enhanced microtubule polymer-
isation and axon growth.
11 Therefore, the function of GSK3b
in the regulation of neural differentiation remains unclear.
Chen et al.
12 reported that WWOX likely has a role in the
development of the nervous system. They found that WWOX
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www.nature.com/cddwas differentially expressed during various stages of brain
development in mice, indicating a potential role for WWOX in
promoting neuronal differentiation and maturation.
12 How-
ever, the molecular mechanism by which WWOX facilitates
neural differentiation has yet to be revealed. In this study, we
demonstrated that WWOX enhances retinoic acid (RA)-
mediated neurite outgrowth and identiﬁed a novel mechanism
through which WWOX promotes neurite outgrowth by inter-
acting with and suppressing GSK3b kinase activity in the
presence of RA. Our ﬁndings suggest that the regulation of
GSK3b activity by WWOX has a vital role in RA-induced
neural-cell differentiation.
Results
WWOX is required for neuronal cell differentiation. RA
can induce neuroblastomal differentiation in SH-SY5Y
cells.
13–15 From 1 to 4 days after RA induction, SH-SY5Y
cells progressively underwent phenotypic changes that were
compatible with neuron-like morphology, characterised by
neurite outgrowth (Figure 1a). The expression of the
neuronal marker bIII-tubulin progressively increased over 4
days of RA treatment (Figure 1b). The expression of cyclin
D1, a cell-cycle progression marker, gradually decreased
during the RA treatment. Increased expression of WWOX
Figure 1 RA-induced SH-SY5Y differentiation is reduced by WWOX knockdown. (a) Morphological changes in SH-SY5Y neuroblastoma cells treated with or without RA
(upperpanel).Thepercentageofdifferentiatedcellswasdeterminedforcellstreatedwith10mMRA,andthephotosweretakenondays0,1,2,3and4(lowerpanel).(b)Cells
were treated with RA for the indicated times and collected for protein extraction. Western blots were conducted to measure the levels of pTau S404, pTau S422, pTauS396,
Tau, WWOX, cyclin D1, phospho-GSK3bS9, GSK3b, b-catenin, phospho-b-catenin and actin. (c) Western blot results of Figure 2b were quantiﬁed by scanning the
autoradiogramusingadensitometer.(d)SH-SY5Ycellsweretransfectedwithtwopre-designedsiRNAtargetingWWOXfor24h,andtheresultingcelllysatesweresubjected
to western blot analysis. (e) SH-SY5Y cells were transfected with either control siRNA or WWOX siRNA as indicated. After 24h of transfection, cells were washed, and the
medium was replaced with 1% serum including 10mM RA. Cells with neurites longer than twice the length of the cell body were counted. Data are presented as the
mean±S.E. from three independent experiments. *Po0.05, **Po0.01 when compared with the mock control
WWOX facilitates neuronal differentiation
H-Y Wang et al
1050
Cell Death and Differentiationwas observed in the RA-treated SH-SY5Y cells,
accompanying the decreased phosphorylation of Tau at
both S396 and S404; phosphorylation at S422 was
unchanged (Figures 1b and c). Since studies have shown
that S404 and S396 may be phosphorylated by GSK3b
in vivo,
16 we also examined whether the phosphorylation
level of GSK3b and its downstream target, b-catenin, are
affected by RA treatment. We found that the phosphorylation
levels of phospho-GSK3b S9 and phospho-b-catenin remained
normal. We therefore suspected that the reduced GSK3b-
mediated Tau phosphorylation and increased WWOX
expression are indispensable for RA-induced SH-SY5Y cell
differentiation. Furthermore, SH-SY5Y cells in which WWOX
expression was reduced by RNAi showed increased pTau
S396 levels and notably decreased neurite outgrowth
(Figures 1d and e). Collectively, these results indicate that
WWOX may have a vital role in SH-SY5Y cell differentiation
and in Tau phosphorylation.
WWOX interacts and colocalises with GSK3b in vivo.
Herna ´ndez et al.
16 demonstrated that S396 and S404
on Tau are GSK3b-dependent phosphorylation sites.
Thus, we presumed that WWOX-dependent dephosphory-
lation of Tau occurred through an inhibition of GSK3b activity.
We performed a bioinformatic analysis to align WWOX with
well-known GSK3b inhibitors (Figure 2a) and found that
WWOX296 320 and WWOX388 412 contain FXXXLI/
VXRLE, a highly conserved GSK3b-binding motif within
GSKIP115 139, Axin381 405, and FRAT205 229. Previous
reports have shown that GID381 405, a 25-amino acid
region of Axin, is critical for its association with GSK3b.
8
Interestingly, WWOX296 320 and WWOX388 412 are similar to
GID381 405 in Axin (Figure 2a). WWOX296 320 is 40% similar
to Axin1381 405, 32% similar to Axin2363 387, 36% similar to
FRAT1205 229 and 34% similar to GSKIP115 139.
WWOX388 412 is 26% similar to Axin1381 405, 34% similar
to Axin2363 387, 36% similar to FRAT1205 229 and 32%
Figure 2 WWOX physically interacts and colocalises with GSK3b in vitro and in vivo.( a) Upper panel: the amino acid sequence of WWOX 296 320, which is similar to
highly conserved regions of Axin1381 405, Axin2363 387, FRAT1205 229 and GSKIP115 139, is highlighted in grey. Lower panel: the amino acid sequence of WWOX 388 412,
which is similar to highly conserved regions of Axin1381 405, Axin2363 387, FRAT1205 229 and GSKIP115 139, is highlighted in grey. Identical amino acids are highlighted in
black. (b) SH-SY5Y cells were co-transfected with pEGFP–GSK3b and pcDNA3.1–HA–WWOX constructs for 24h. Cells were ﬁxed with 3.7% formaldehyde, permeabilised,
and incubated with mouse anti-HA primary antibodies and rhodamine-conjugated secondary antibodies. The cells were then observed using a Zeiss LSM510 confocal
microscope. (c) Cells were harvested for immunoprecipitation using anti-WWOX (left) or anti-GSK3b (right) antibodies. WWOX-associated GSK3b was recognised by anti-
GSK3b.Anti-HAwas usedtodetect overexpressed HA-tagged WWOX.(d)SH-SY5YcellsweretransientlytransfectedwiththeWWOX–HAconstructandtreatedwith RAfor
24h. The cells were harvested for immunoprecipitation with anti-GSK3b. Immunoprecipitated GSK3b was recognised by antibodies against GSK3b. Anti-HA was used to
detectHA-taggedWWOX.(e)Mousebrainextractwassubjectedtoimmunoprecipitationusinganti-WWOXoranti-GSK3basindicated.Theimmunoprecipitatedcomplexwas
separated by molecular weight using SDS-PAGE. Anti-WWOX or anti-GSK3b antibodies were used to detect WWOX or GSK3b on the PVDF membrane
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Cell Death and Differentiationsimilar to GSKIP115 139 (Figure 2a). These results suggested
that WWOX may interact with GSK3b. Hence, we performed
immunoﬂuorescence and immunoprecipitation experiments
to determine whether WWOX is associated with GSK3b.
First, SH-SY5Y cells were co-transfected with plasmids
expressing GSK3b fused to green ﬂuorescent protein
(GFP) (GFP–GSK3b) and WWOX–HA to examine the
in vivo association of WWOX and GSK3b. Confocal
ﬂuorescent microscopy demonstrated that WWOX and
GSK3b colocalised in the cytoplasm of SH-SY5Y cells
(Figure 2b). We then performed co-immunoprecipitation
experiments to conﬁrm the in vivo interaction between
WWOX and GSK3b in SH-SY5Y cells. Cell extracts were
prepared from SH-SY5Y cells that had been transiently
transfected with the WWOX–HA construct. Figure 2c (left
panel) shows that the anti-HA antibodies precipitated
HA-tagged WWOX, and that endogenous GSK3b co-
precipitated with the WWOX protein complex. Similarly,
ectopic HA-tagged WWOX was co-immunoprecipitated by
anti-GSK3b antibodies (Figure 2c, right panel).
We considered the possibility that WWOX could regulate
Tau phosphorylation through direct interaction. In Supple-
mentary Figure A, however, we show that although WWOX–
HA can be immunoprecipitated with anti-HA antibodies, Tau
was not co-immunoprecipitated in the complex (Supplemen-
tary Figure A), indicating that WWOX does not stably interact
with Tau in SH-SY5Y cells. To clarify whether the interaction
between WWOX and GSK3b is affected by RA treatment, we
performed co-immunoprecipitation experiments in cells that
had been stimulated with RA. SH-SY5Y cells were transiently
transfected with the WWOX construct to mimic the upregula-
tion of WWOX by RA treatment. Figure 2d shows that the
amount of GSK3b co-immunoprecipitated by WWOX from
RA-treated SH-SY5Y cells was similar to the amount
precipitated in untreated controls. Subsequently, immunopre-
cipitation was performed in mouse brain extracts to verify the
physiological interaction between WWOX and GSK3b.
Figure 2e shows that both GSK3b and WWOX were
precipitated by anti-GSK3b or anti-WWOX antibodies. These
results indicate that WWOX physiologically associates and
colocalises with GSK3b in vivo.
The WWOX–GSK3B interaction is mediated by a
conserved motif in WWOX. To narrow down the binding
site on WWOX that is responsible for its binding to GSK3b,
various WWOX functional domains, ww1 (1–60a.a.), ww2
(40–110a.a.), ww (1–110a.a.) and ADH (110–414a.a.),
were expressed as glutathione S-transferase (GST) fusions
in E. coli and afﬁnity-puriﬁed on glutathione beads
(Figure 3a). As shown in Figure 3b, the result of GST pull-
down assay reveals an intense anti-GSK3b band was bound
by the full-length WWOX and ADH-domain afﬁnity matrix
(Figure 3b, lanes 6 and 7), but not by GST alone (lane 2) or
the other WWOX domains (lanes 3–5) examined. These
results suggest that GSK3b interacts with WWOX by binding
to its ADH domain.
Additionally, the GST pull-down assay demonstrated
that neither WWOX-D389 (1–389a.a.) nor WWOX-D286
(1–286a.a.) were able to interact with GSK3b (Figure 3c).
This indicates that WWOX amino acids 388–407 are required
for its interaction with GSK3b. Furthermore, bioinformatics
analyses revealed that L404 was highly conserved in WWOX
and other GSK3b-binding proteins (Figure 2a). In order to
clarify whether L404 within the highly conserved GSK3b-
binding motif, LXXRL, has an important role in GSK3b
binding, a GST pull-down assay was performed using two
WWOX mutants, L404A and L311A. As shown in Figure 3d,
the mutation of L404A, but not L311A, completely abolishes
the binding of WWOX to GSK3b. These results suggest that
WWOX physically interacts with GSK3b in vitro through the
L404-containing motif within the WWOX388 407 region.
Finally, the co-immunoprecipitation experiment was per-
formed again to compare wild-type (WT) WWOX with these
mutants. As expected, ectopic GFP–WWOX can be
co-immunoprecipitated by endogenous GSK3b, and this
interaction was diminished when L404 mutated to alanine
(Figure 3e, right panel). Similar results were found in a
co-immunoprecipitation experiment using GFP antibodies
against GFP-tagged WWOX proteins (Figure 3e, left panel).
To investigate the possibility that the L404 mutant is
incorrectlyfolded,thusdisruptingGSK3b–WWOXinteraction,
we conducted co-immunoprecipitation experiments using
c-jun, a WWOX-binding protein. C-jun was immunoprecipi-
tated by either WT or mutant WWOX–GFP, indicating that
WWOX L404A is folded correctly.
17 To understand how
WWOX associates with GSK3b, we simulated the interaction
in silico using molecular modelling. Figure 3f illustrates the
interactionbetweenGSK3bandWWOX388 407.Theoverview
in Figure 3f shows that the motif portion of WWOX388 407
(highlighted in light pink and dark pink, respectively),
especially L400, R403 and L404, are in close contact with a
binding pocket a-helix (G262-L273, red) and loop (N285-
H299, green) on GSK3b. Figures 3g and h and Supplemen-
tary Figure B show close-up views of WWOX388 407 inter-
acting with the binding pocket a-helix and loop, respectively.
As indicated in Figure 3g, the interactions between
WWOX388 407andthebindingpocketa-helixarehydrophobic
(indicated by red dashed lines) and electrostatic (indicated by
green dashed lines). The van der Waals interactions included
WWOX388 407 L400 with a number of consecutive hydro-
phobic residues, including V263, L266, V267 and I270;
WWOX388 407 L404 with V267 and L270; and WWOX388 407
A399 with V263. A similar helix–helix ridge-groove hydro-
phobic interaction was also present in the GSK3b–GSKIP-
tide
18 and GSK3b–AxinGID
19 structures. Similarly, the
contact between WWOX388 407 and the GSK3b-binding loop
was a simple hydrophobic interaction between L400 and
F293, and between L404 and I296. Collectively, these results
revealed that the L404-containing motif located within
WWOX388 407 is essential for the association of WWOX and
GSK3b.
GSK3b kinase activity is negatively regulated by
WWOX. We next investigated the functional effect of
WWOX in regulating GSK3b activity. We performed an
in vitro kinase assay to examine whether WWOX interferes
with GSK3b-mediated Tau phosphorylation. GST-tagged
WWOX protein (0.3mg) and His-GSK3b protein (30ng)
were incubated in reaction buffer for 30min before
adding 0.5mg His-Tau protein and a [g-
32P] ATP cocktail.
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Cell Death and DifferentiationThe GSK3b-mediated Tau phosphorylation was examined by
autoradiography and western blotting analysis. As shown in
Figure 4a, GSK3b can phosphorylate Tau in vitro, and this
phosphorylation is completely abolished in the presence of
excess WWOX, but not GST or WWOX L404A. Moreover,
we demonstrated that GSK3b-mediated Tau phosphorylation
at S396 and S404 was reduced in a dose-dependent manner
by GST–WWOX (Figure 4b). In the same experiment, we
investigated the speciﬁcity of the effect of WWOX on GSK3b-
mediated Tau phosphorylation by examining the
phosphorylation of S422, which is phosphorylated by MKK4
kinase in vivo (Figure 4c). SH-SY5Y cells were transiently
transfected with GFP and GFP–WWOX for 12h, and the
cell lysate was subjected to western blotting. Ectopically
Figure 3 Leucine 404 within the ADH domain is critical for WWOX associated with GSK3b.( a) WWOX constructs used in this study. Full-length WWOX, ww1, ww2, ww,
ADHdomainandmutantWWOX(L311AandL404A)were clonedinto a GST-fusionproteinexpressionvector. Twopartialdeletionsof the WWOXADHdomainare indicated
(D389 and D286). (b) Each GST-tagged WWOX construct was prepared and incubated with cell lysates in a binding buffer. Equivalent loading of the proteins was conﬁrmed
using Coomassie blue staining. Western blot analysis with anti-GSK3b antibodies was used to verify the interaction domain. (c) GST, WWOX and two WWOX-derived GST-
fusion proteins (D389 and D286) were analysed in a GST pull-down assay. (d) GST pull-down assay with GST or GST-fused mutant WWOX (L311A and L404A). (e) SH-
SY5Y cells were transfected with GFP, GFP–WWOX or GFP–WWOXL404A and harvested for immunoprecipitation with anti-GSK3b. Anti-GFP was used to detect
GFP–WWOX. (f–h) Molecular modelling of the WWOX–GSK3b interaction. (f) An overview of the interaction of WWOX388 407 and GSK3b.( g) A close-up view of the
interface between the GSK3b binding-pocket a-helix and WWOX388 407. The two binding partners are shown at a distance for clarity. (h) A close-up view of the interface
between the GSK3b-binding pocket loop and WWOX388 407. The two binding partners are shown at a distance for clarity. Colour code: WWOX388 407, pink; GSK3b-binding
pocket a-helix, red; GSK3b-binding pocket loop, green; GSK3b non-interacting regions, blue. Red dashed lines indicate electrostatic interactions, namely hydrogen bonds or
salt bridges; green dashed lines indicate hydrophobic interactions
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Cell Death and Differentiationexpressed WWOX signiﬁcantly inhibited Tau phosphorylation
at S404 and S396 but not S422. However, this inhibition was
diminished when WWOX L404A was used. These results
again conﬁrm our ﬁnding that the binding of WWOX to
GSK3b is required for its inhibition of GSK3b-mediated Tau
phosphorylation. The phosphorylation of Tau S422 is not
affected by WWOX (Figure 4c), suggesting that the inhibition
of GSK3b through the binding of WWOX is highly speciﬁc, at
least in SH-SY5Y cells. Moreover, we examined the effect of
WWOX on the activity of GSK3b toward the peptide
substrate GS-1, which is derived from glycogen synthase.
Consistent with our observations of Tau phosphorylation, WT
but not mutant WWOX inhibits GSK3b phosphorylation of
GS-1 (Supplementary Figure C).
We subsequently performed a competitive inhibition assay
to further support our conclusion using WWOXtide388 407,a
WWOX-derived peptide, in the in vitro kinase assay experi-
ment. WWOXtide388 407, but not the control scrambled
peptide, inhibited GSK3b activity and reduced Tau phosphory-
lation, as shown by autoradiography (Figure 4d). Collectively,
Figure 4 WWOXsuppressesTau phosphorylation.(a)GST, GST–WWOXor GST–WWOXL404A(0.2mg) were incubatedwith 30ng His-GSK3b for 30min in a reaction
bufferandincubatedwith0.5mgTauprotein,ATPcocktail,and10Ciof[g-
32P]ATPfor10minat201C.Thereactionwasstoppedbyadding2  samplebufferandheatingat
1001C for 10min. This was followed by SDS-PAGE, and phosphorylation signals were evaluated using autoradiography. (b) WWOX (1, 3 and 10mg) inhibited Tau
phosphorylation by GSK3b in a dose-dependent manner. GST–WWOX was pre-incubated with His-GSK3b for 30min in a reaction buffer including optimised quantities of
ATP and Tau protein. The reactions were then subjected to western blot analysis of Tau, pTauS396 and S404. (c) SH-SY5Y cells were transiently transfected with GFP,
GFP–WWOXorGFP–WWOXL404A.Cellswerelysed,andawesternblotanalysiswascarriedoutusingantibodiesagainstpTauS396,pTauS404,pTauS422,Tauandactin.
Actin expression was evaluated to verify equal loading, and GFP expression was evaluated to conﬁrm the protein expression level. (d) A scrambled peptide and
WWOXtide388 407 were each incubated with 30ng His-GSK3b, ATP-cocktail, and 10 Ci of [g-
32P] ATP for 10min at 201C. The reaction was stopped by adding 2  sample
buffer and was followed by SDS-PAGE. Phosphorylation was detected with autoradiography
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Cell Death and Differentiationour results reveal that WWOX negatively regulates GSK3b
kinase activity on the neuron-speciﬁc microtubule-binding
protein Tau in SH-SY5Y cells.
WWOX promotes neuronal cell differentiation through
the inhibition of GSK3b. Researchers have suggested
that GSK3b has an important role in cell differentiation.
We therefore investigated whether GSK3b inactivation is
involved in RA-stimulated neuronal cell differentiation.
SH-SY5Y cells were transiently transfected with a GFP control
or GSK3b (WT, S9A or kinase dead (KD), or R96A) for
24h, and the neurite outgrowth of SH-SY5Y cells, indicating
neuronal cell differentiation, was analysed. Transfection with
GFP–GSK3b WT and S9A notably decreased SH-SY5Y
cell differentiation, whereas KD and R96A did not affect
SH-SY5Y cell differentiation compared with the GFP control
(Figures 5a and b). GSK3b small interference RNA (siRNA)
was used to knock down GSK3b protein expression to
conﬁrm the crucial role of GSK3b inactivation in RA-mediated
axon growth. SH-SY5Y cells were transfected with GSK3b
siRNA, followed by treatment with 10mM RA for 1 to 4 days.
Compared with the control scrambled-RNAi group, the
GSK3b protein-knockdown group showed signiﬁcantly
increased neurite outgrowth percentage beginning on the
second day of RA treatment (Figures 5c and d). Thus, our
results showed that GSK3b could negatively regulate neurite
outgrowth in RA-stimulated neuronal cells.
Microtubule polymerisation is indispensable in neurons
because neurite growth is severely disrupted when polymer-
isation is inhibited, indicating that a constant ﬂux of micro-
tubules is required for axonal growth. Furthermore, evidence
shows that the phosphorylation of Tau by GSK3b affects the
ability of Tau to promote microtubule formation.
20–22 This
evidence, in addition to the results of this study, suggests that
WWOX may promote neuronal cell differentiation by inhibiting
GSK3b-mediated Tau phosphorylation. We therefore used a
light-scattering assay to clarify how WWOX and GSK3b affect
Tau-mediated microtubule assembly. As shown in Figure 5e,
we measured the effect of GSK3b on the turbidimetric time
course of microtubule assembly. GSK3b diminished the
microtubule assembly, as reﬂected by decreased turbidity.
However, the new equilibrium reached a higher turbidity when
treated with WT WWOX and GSK3b than with GSK3b alone.
Interestingly, the GSK3b-binding deﬁcient WWOX, WWOX
L404A, could not restore the microtubule assembly activity. In
conclusion, our data demonstrated that WWOX could restore
the ability of Tau to promote microtubule formation by
inhibiting GSK3b activity.
WWOX L404A, which is deﬁcient in binding to GSK3b
(Figure 3) and was incapable of restoring Tau activity on
microtubule formation (Figure 5e), should fail to stimulate
neuronal cell differentiation. To conﬁrm this prediction, the
SH-SY5Y cell differentiation promoted by WWOX L404A was
examined and compared with that of WT WWOX. WT WWOX
and WWOX L404A were separately overexpressed in
SH-SY5Y in the presence of RA treatment. WWOX signiﬁ-
cantly increased the percentage of differentiated SH-SY5Y
cells. However, this increase was abolished when L404
was mutated to alanine. These results strongly suggest that
WWOX promotes neuronal differentiation in SH-SY5Y cells
by inhibiting the GSK3b-mediated phosphorylation of the
microtubule-binding protein Tau (Figures 5f and g).
To demonstrate that Tau is indeed the ultimate effector of
WWOX/GSK3b-dependent neuronal cell differentiation, we
performed double manipulation of WWOX and GSK3b,a s
well as the delivering of siRNA to knock down Tau and
GSK3b,respectively, and then conductedRA-induced neurite
outgrowth experiments. Figures 6a and b (lanes 1–3) show
that the neurite outgrowth stimulated by RA was abolished
when Tau was knocked down. Western blotting (Figure 6b)
conﬁrmed protein overexpression or knockdown after tran-
sient transfection of the WWOX-expressing vector or Tau and
GSK3b siRNAs. Neuronal differentiation increased to 44% in
the WWOX overexpression group comparing with 18% of RA-
control cells group (lane 6). This increase was completely
abolished when Tau was knocked down in a double
manipulation experiment (lane 5). Similar results were
exhibited in a GSK3b and Tau double manipulation experi-
ment, which showed that neuronal cell differentiation of the
GSK3bknockdowngroupincreasedapproximately25%more
than the RA-control (lane 7), which was completely abolished
when Tau was knocked down (lane 4). Neither WWOX
overexpression nor GSK3b knockdown promoted neurite
outgrowth inthe Tauknockdown condition, indicatingthatTau
is the effector of both WWOX and GSK3b (Figures 6a and b).
Interestingly, co-transfection of the WWOX plasmid and
GSK3b siRNA followed by RA treatment did not show an
additive or synergistic effect compared with WWOX over-
expression alone or GSK3b knockdown alone (Figures 6a
and b, lane 8). WWOX did not further promote neurite
outgrowth in the presence of GSK3b siRNA, consistent with
the hypothesis that WWOX promotes neuronal differentia-
tion through GSK3b inhibition. Collectively, these results
connect WWOX, GSK3b and Tau in an exclusive, direct
manner and show that WWOX promotes neuronal SH-SY5Y
cell differentiation through inhibiting the GSK3b-mediated
phosphorylation of the microtubule-binding protein, Tau.
Discussion
In this study, we found two GSK3b consensus-binding sites in
the WWOX amino-acid sequence. Furthermore, our results
show that WWOX physically interacts with GSK3b only
through the WWOX388 407 region, which is an L404-contain-
ing motif.SomereportssuggestthatL400isalsoimportantfor
WWOX to associate with GSK3b. Smalley et al.
19 demon-
strated that L392 and L396 are essential for the interaction
between Axin1 and GSK3b. Interestingly, the L392 and L396
of Axin1 are related to L400 and L404, respectively. These
results show that WWOX interacts with GSK3b through a
structure and sequence similar to that of Axin381 405.
Furthermore, researchers have suggested that GSK3b has
an important role in multiple cellular processes, including
protein synthesis, glycogen metabolism, proliferation, micro-
tubule dynamicsandcell differentiation.
23WWOXmayhelpto
control certain types of cellular processes through the
inhibition of GSK3b.
WWOX expression in the developing brain is low during the
early embryonic stage when organogenesis is most rapid;
however, moderate-to-high WWOX immunoreactivity is
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Cell Death and Differentiationdetected in the brain and spinal cord during the middle and
late fetal stages.
12 This strongly suggests that WWOX may
have an important role in neuron differentiation. In this study,
highly differentiated SH-SY5Y cells were correlated with high
WWOX protein expression and low Tau S396 and S404
protein phosphorylation. This indicates that SH-SY5Y cell
differentiation requires WWOX protein expression and
lower pTau S396 and pTau S404 levels, possibly caused by
the inhibition of GSK3b. Intriguingly, Sze’s group demon-
strated that the downregulation of WWOX induces
Figure 5 WWOX regulates neuronal differentiation through its interaction with GSK3b.( a) SH-SY5Y cells were transfected with GFP, GFP–GSK3b WT, S9A, K8586MI
and R96A for 24h. The cells were then treated with 10mM RA for 24h. Cells with neurites longer than twice the length of the cell body were counted. Data are presented
as the mean±S.E. from three independent experiments. **Po0.01 compared with the GFP control. (b) Western blot analysis conﬁrmed the expression of the GFP-fusion
proteinbytheanti-GFPantibody.(c)SH-SY5Ycellsweretransfectedwith pre-designed siRNAtargetingGSK3bfor 24handtreatedwith 10mMRAfor 1to 4days.Cellswith
neurites longer than twice the length of the cell body were counted. Bright-ﬁeld results are shown to indicate post-differentiation status at 24h. Data are presented as the
mean±S.E. from three independent experiments. *Po0.05 compared with mock control. (d) Cells were treated with siRNA and lysed in 2  sample buffer. Western blot
analysis was carried out using antibodies against GSK3b. The blot was stained for actin to verify equal loading. (e) Tau protein was incubated with GST, GST–WWOX or
GST–WWOX L404A in the presence of GSK3b for the microtubule assembly assay. The reaction mixture also contained tubulin protein, GTP, and reaction buffer. The
reaction mixture was incubated at 371C in a thermostatic spectrophotometer, and the change in reﬂectance over time was measured at 350nm. (f) SH-SY5Y cells were
transfected with empty vector, GFP–WWOX or GFP–WWOXL404A, as indicated. After transfection, cells were washed, and the medium was replaced with 1% serum and
treated with 10mM RA. The photos were taken on day 1. (g) The percentage of differentiated cells with neurites longer than twice the length of the cell body was calculated.
The data are presented as the mean±S.E. from three independent experiments. *Po0.05 compared with the mock-treated control
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Cell Death and DifferentiationTau phosphorylation. They also showed that WWOX was
downregulated in AD patients.
2 Furthermore, the level of
active GSK3b is reportedly increased in AD.
24 Based on our
results, we speculate that the upregulation of GSK3b, and
therefore Tau phosphorylation, in AD may due to the down-
regulation of WWOX.
Chen et al.
12 reported that WWOX was differentially
expressed during various stages of brain development in
mice, indicating its potential role in promoting neuronal
differentiation and maturation. They also used a yeast
two-hybrid assay to demonstrate that WWOX associates with
Tau and showed that the downregulation of WWOX may
induce Tau phosphorylation in vitro.
2 However, the molecular
mechanism by which WWOX facilitates neural differentiation
has yet to be revealed. Here, we were not able to detect a
Tau–WWOX complex in our co-immunoprecipitation experi-
ment from SH-SY5Y cells (Supplementary Figure A); the
inconsistency in results may due to the different expression
systems used. However, our results connect WWOX, GSK3b
and Tau in an exclusive, direct manner and describe a novel
Figure 6 Tau is indispensable for WWOX regulation of neuronal differentiation. (a) SH-SY5Y cells were transfected with Tau siRNA, GSK3b siRNA and WWOX together
or separately for 24h. They were then treated with 10mM RA for another 24h. The photos were taken on day 1. (b) The percentage of differentiated cells with neurites longer
than twice the length of the cell body was calculated. (c) Cells treated with Tau and GSK3b siRNA and WWOX plasmid were lysed in 2  sample buffer, and a western blot
analysis was carried out using antibodies against Tau, WWOX and GSK3b.( d) Our proposed model, showing that WWOX abolishes GSK3b kinase activity and therefore
restores the ability of Tau to promote microtubule assembly
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cell differentiation by inhibiting the GSK3b-mediated phos-
phorylation of the microtubule-binding protein, Tau.
The extension of immature neurites requires the assembly
of a stable microtubule infrastructure. Microtubule polymer-
isation and stability are regulated by a number of microtubule-
associated proteins, including Tau. GSK3b regulates Tau
through phosphorylation; hyperphosphorylated Tau has a
decreased afﬁnity for microtubules and disrupts microtubule
stability. This study shows that the knockdown of GSK3b
expressionthroughRNAidecreasesTauphosphorylationand
increases the occurrence of SH-SY5Y cell differentiation.
Additionally,researchershavereportedthattheinactivationof
GSK3b results in the dephosphorylation of the GSK3b
downstream target, CRMP-2, which leads to enhanced
microtubule polymerisation and axon growth.
11 Therefore,
neurite outgrowth requires microtubule assembly and the
inhibition of GSK3b activity. However, a number of previous
studies have reported that the activation of GSK3b enhanced
neurite growth rates in PC12, NT2 or SH-SY5Y cells.
25–27
However, our microtubule assembly assay clearly showed
that WWOX restores the microtubule assembly-promoting
activity of Tau that is repressed by GSK3b. Ahmad et al.
21
reported that the inhibition of microtubule polymerisation
compromises axonal growth. We observed highly phosphory-
lated Tau in undifferentiated SH-SY5Y cells. Reduced Tau
phosphorylation also correlated strongly with WWOX expres-
sion in highly differentiated SH-SY5Y cells. These results
provide evidence that WWOX has an important role in
inhibiting GSK3b activity and suppressing Tau hyperpho-
sphorylation.
In conclusion, our study demonstrates that WWOX physi-
cally interacts with GSK3b through its ADH/SDR domain and
decreases Tau protein hyperphosphorylation at S404 and
S396, both in vivo and in vitro. Furthermore, we showed that
an increased WWOX protein level is correlated with
decreased pTau S396 and S404 levels in highly differentiated
SH-SY5Y cells. The microtubule assembly will eventually be
promoted by Tau when GSK3b is inhibited by WWOX during
RA-stimulated neuronal cell differentiation. We thus present a
novel mechanism for the regulation of neuronal differentiation
by WWOX.
Materials and Methods
Cell culture, transfection and treatments. Human neuroblastoma
SH-SY5Y cells were maintained in Dulbecco’s Modiﬁed Eagle’s Medium supplemented
with 10% fetal calf serum and antibiotics (100mg/ml streptomycin and 100IU/ml
penicillin; Life Technologies, Inc., Gaithersburg,MD, USA). The cells were grown to
subconﬂuence and then treated with 10mM RA for 1 to 5 days. The information of
siRNA used in this study was provided in Supplementary Table 1. For efﬁcient
transfection, Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) was used
according to the manufacturer’s instructions.
Plasmid construction. A full-length WWOX (human WOX1) construct was
subcloned into the following expression vectors: pEGFP-C1-CPO, pGEX-KG and
pcDNA3.1-HA-CPO. The ADH domain fragment was generated by PCR with
pfu polymerase (Promega, Madison, WI, USA). The PCR product was subcloned
into the pGEX-KG, pEGFP-C1-CPO and pcDNA3.1-HA-CPO plasmids for
sequence veriﬁcation and further cloning.
WWOX mutants (L311A and L404A) were prepared using site-directed
mutagenesis and a two-step PCR technique. After successful cloning, the WWOX
cDNA insert sequences were further conﬁrmed through DNA sequencing.
Western blotting. Cells were disrupted in 2X sample buffer (0.1M Tris-HCl
pH 6.8, 4% SDS, 20% glycerol, 2% b-mercaptoethanol), boiled for 10min, centri-
fuged, placed on ice for several minutes, stored at  801C and then separated
using 10–12.5% SDS-polyacrylamide gel electrophoresis (PAGE). Proteins were
then electrotransferred onto PVDF transfer membranes (Millipore, Lincoln Park, NJ,
USA). The membranes were blocked with 5% nonfat milk in TBST buffer (10mM
Tris-HCl pH 7.4, 150mM NaCl, 0.5% Tween 20) containing 5% bovine serum
albumin at 41C for 2h or overnight, and incubated for 2h at room temperature with
one of the following primary antibodies: monoclonal anti-GFP (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), anti-GSK3b (BD Transduction
Laboratories, Lexington, KY, USA), monoclonal anti-actin (Sigma, St. Louis, MO,
USA), Tau (Millipore), rabbit anti-pTau S396 (Origene, Rockville, MD, USA), rabbit
anti-pTau S404 (Millipore) or rabbit anti-pTauS422 (Abcam, London, UK). The
membranes were washed with TBST six times every 10min. Immunoreactive
proteins were detected using horseradish peroxidase-conjugated secondary
antibodies and then the membrane was washed with TBST six times every
10min during the detection process. The protein signal was detected by an
enhanced chemiluminescence system (ECL Plus; Perkin Elmer Life and Analytical
Sciences, Inc., Waltham, MA, USA).
Immunoprecipitation and GST pull-down assays. For
immunoprecipitation, SH-SY5Y cells were washed twice with phosphate-buffered
saline (PBS) at the indicated times and lysed in ice-cold RIPA buffer (100mM
HEPES pH 7.4, 150mM NaCl, 2mM EDTA, 0.5% Tween 20, 0.1% Triton X-100,
1mMDTT,50mg/mlAEBSF,10mg/mlleupeptin,10mg/mlaprotinin,5mMNaFand
1mMNa 3VO4). Anti-WWOX antibodies were incubated with Protein G-Sepharose
beads for 1h at 41C, and the pretreated cell lysates were added to the Protein
G-Sepharose beads for 2h at 41C. The immune complexes were then washed
three times with a RIPA buffer, eluted by boiling in a 2X SDS sample buffer, and
subjected to western blotting analysis. For GST pull-down assays, GST or GST–
WWOX proteins expressed in BL21 (DE3) were adsorbed to glutathione-agarose
beads (Sigma) for 1h after three washes with PBS. The beads were then washed
three times with the same buffer. Sample buffer was added, and the beads were
boiled and subjected to western blot analysis.
Immunoﬂuorescence assays. SH-SY5Y cells co-transfected with
pcDNA3.1–HA–WWOX and GFP–GSK3b were grown on coverslips, washed in
PBS,ﬁxedwith 3.7%paraformaldehydein PBS,and permeabilised by incubationin
10% Triton X-100. Following permeabilisation, the cells were washed with PBS and
incubated with a mouse anti-HA monoclonal antibody (Santa Cruz Biotechnology)
at 41C overnight. The cells were washed again and then incubated with goat
anti-mouse IgG rhodamine (Santa Cruz Biotechnology). The cells were washed
againand subsequentlystained with DAPI. In eachinstance,the cellswere washed
inPBS.FluorescentlylabelledproteinlocalisationwasvisualisedusingaZeisslaser
confocal microscope (LSM510; Zeiss Inc, Oberkochen, Germany).
In vitro kinase assay. His-tagged human Tau and His-tagged human GSK3b
were expressed in E.coli BL21 and puriﬁed by means of afﬁnity chromatography. The
purity of the recombinant proteins was veriﬁed by SDS-PAGE. The puriﬁed
recombinant GSK3b protein was pre-incubated with WT or mutant GST–WWOX
and 25mg/ml His-Tau for 30min, and the kinase reaction was initiated by the addition
ofanequalvolumeof2Xreactionbuffer(100mMHEPES,pH7.4,1mMDTTand10%
glycerol) and ATP cocktail (20mM ATP and 1mM MgCl2). After incubating the
mixtures at 301C for up to 20min, the reaction was stopped by adding 2  sample
buffer and heating at 1001C for 10min. The proteins were further separated using
SDS-PAGE. Results were detected using autoradiography or western blotting.
Molecular dynamics simulation. A molecular dynamics (MDs) simulation
was employed to predict the binding interaction between GSK3b and
WWOX388 407. As the structure of WWOX is unknown, the GOR IV Secondary
Structure Prediction Method
28 was used to predict the structure of the
WWOX388 407 peptide. Accordingly, the structure of the GSK3b–AxinGID
complex (PDB entry code: 1O9U) was used as a template to create an initial
structure for the GSK3b–WWOX388 407 complex. The structure of AxinGID was
extracted from the complex, and the amino acids were modiﬁed to generate
WWOX388 407. The resulting WWOX388 407 peptide was then subjected to energy
minimisation in which the backbone was constrained and the side chains were
allowed to achieve their proper orientations using 5000 steps of the steepest
descent algorithm and 5000 steps of the conjugate gradient algorithm. The X-ray
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GSK3b-binding pocket, which was composed of an a-helix, G262-L273, and an
extended loop from N285 to H299. Energy minimisation was applied to eliminate
any residual geometrical strain caused by placing WWOX388 407 in the GSK3b-
binding pocket. Energy minimisation was achieved by performing 5000 steps of the
steepest descent algorithm and 5000 steps of the conjugate gradient algorithm.
The MD simulations in this study were performed according to the standard
protocol, whichconsistsof gradualheating,equilibration andproductionprocedures
in an isothermal isobaric ensemble (NPT, P¼1 a.t.m. and T¼300K) MD. A
minimised, solvated system was used as the initial structure for subsequent MD
simulations. In the 150p.s. heating procedure, the system was gradually heated
from 50 to 300K at a rate of 2.4K/1p.s., followed by constant equilibration at 300K
for 150p.s. After the equilibration procedure, the system underwent a 2n.s.
production procedure for conformation collection. The time step was set at 1f.s. A
snapshot was taken every 5p.s. to record the conformation trajectory during MD
production. A 12- A ˚ cutoff was applied to treat non-bonding interactions, such as
short-range electrostatic and van der Waals interactions. The particle-mesh-Ewald
(PME) method was applied to treat long-range electrostatic interactions. All
simulations were performed using Accelrys’ Discovery Studio software with a
CHARMM force ﬁeld. The SHAKE algorithm was used to constrain all bonds
containing hydrogen bonds to their equilibrium lengths.
Microtubule assembly assay. Microtubule assembly assays were
performed by incubating tubulin (0.2mg/ml) (Cytoskeleton; Denver, CO, USA) in
cuvettes at 371C in a thermostatic spectrophotometer and measuring the turbidity
change at 350nm over time. To examine the effects of WWOX and GSK3b on
tubulin polymerisation, the GSK3b was pre-incubated with Tau in the presence of
WWOX for 30min, and polymerisation was then initiated by the addition of 1mM
GTP and followed by a light-scattering assay.
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